Take a look at some of our published work

Caregiver burden associated with caring for individuals with tuberous sclerosis complex-associated seizures: A descriptive, non-interventional survey in Sweden

Siu Hing Lo, Hanna Skrobanski, Miranda Harrison, Jamshaed Siddiqui, Sally Bowditch

Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States

Monteleone, B., Forster, K., Chua, G.N. et al. Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States. Health Qual Life Outcomes 23, 7 (2025).

See study

Using the EQ-5D to measure caregiver health-related quality of life in rare pediatric disease: a study in aromatic L-amino acid decarboxylase deficiency

Acaster, S., Williams, K., Skrobanski, H., Buesch, K. (2022). Using the EQ-5D to measure caregiver health-related quality of life in rare pediatric disease: a study in aromatic L-amino acid decarboxylase deficiency. Future Neurology, 17, 2.

See study

Symptoms and impacts of aromatic L-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function

Williams K., Skrobanski, H., Buesch, K., Acaster, S. (2022). Symptoms and impacts of aromatic l-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function. Orphanet J Rare Dis, 17: 128.

See study

Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers

Gallop, K. Acaster, S., de Vries, J., Browne, R., Ryan, R., Bker, S., Du Toit, G. (2022). Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers. Patient Preference and Adherence, 16, 1269-1278.

See study

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom

Lo, SH., Gorni, K., Sutherland, CS., Marti, Y., Lloyd, AJ., Paracha, N. (2022). Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. Pharmacoeconomics, 40, 91-102.

See study

Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries

Lo, SH., Lawrence, C., Gorni, K., Sutherland, CS., Marti, Y., Lloyd, AJ., Paracha, N. (2022). Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. Pharmacoeconomics, 40, 91-102.

See study

Get in touch for bespoke solutions

Reach out

Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States

Lo, SH., Lloyd, AJ., Elkhalifa, S., Sisic, Z., van Nooten, FE. (2022). Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. Pharmacoeconomics Open, 6, 231-239.

See study

Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex

Lo, SH., Marshall, J., Skrobanski, H., Lloyd, A. (2022). Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. Pharmacoeconomics Open, 6, 105-121.

See study

The EQ-5D and the EuroQol Group

Lloyd AJ & Pickard SA. (2019). Value in Health, 22(1), 21-22.

See study

Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model

Williams K., Davidson, I., Rance, M., Boehnke, A., Buesch, K., Acaster, S. (2021). Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model. Journal of Patient-Reported Outcomes.

See study

Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report

Brazier J, Ara R, Azzabi I ... Lloyd AJ, Paisley MA & Pickard SA. (2019). Value in Health, 22(3), 267-275.

See study

Patient reported outcome and observer reported outcome assessment in rare disease trials

Acaster, S. (2017) Value in Health, 20(7)

See study

Special Edition on Utility Measurement

Lloyd, AJ PharmacoEconomics (2017). 35(Suppl 1): 5

See study

See study

Leffler D, Acaster S, Gallop K, Dennis M, Adelman D. (2017) Value in Health

A novel patient-derived conceptual model of the impact of coeliac disease in adults: Implications for patient-reported outcome and health-related quality of life instrument development

Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment

Lloyd AJ, Gallop K, Ali S, Hughes D & MacCulloch A. (2017) Current medical research and opinion, 33(1), 23-29

See study

EQ-5D: Moving from Three Levels to Five

Lloyd AJ Value Health 2018 21, 57–58

See study

Get in touch

See research insights on our blog: Notes by Acaster Lloyd

Go to blog